Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ProQR Therapeutics NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
ProQR Therapeutics Enters into Agreement with EB Research Partnership and EB Medical Research Foundation 11
Foundation Fighting Blindness and ProQR Therapeutics Enter into Agreement 12
ProQR Therapeutics and Galapagos Enter into Research Agreeement 13
Licensing Agreements 14
ProQR Therapeutics Signs License Agreement with Inserm Transfert and Assistance-Publique-Hopiteaux de Paris 14
ProQR Therapeutics Enters into Licensing Agreement with Leiden University Medical Center 15
ProQR Therapeutics Enters into Licensing Agreement with Cystic Fibrosis Foundation 16
ProQR Therapeutics Enters into Licensing Agreement with Radboud University Medical Center 17
ProQR Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 18
Equity Offering 19
ProQR Therapeutics Raises USD104.1 Million in Public Offering of Shares 19
Proqr Therapeutics Prices Public Offering of Shares for USD16.1 Million 21
Proqr Therapeutics Prices Private Placement of Shares for USD4.6 Million 22
Amylon Therapeutics Spin Out from ProQR Therapeutics 23
ProQR Therapeutics to Raise USD6 Million in Private Placement of Shares 24
ProQR Therapeutics Raises USD112 Million in IPO 25
ProQR Therapeutics NV – Key Competitors 27
ProQR Therapeutics NV – Key Employees 28
ProQR Therapeutics NV – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Strategy And Business Planning 30
Sep 12, 2017: ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics 30
Financial Announcements 31
Aug 08, 2018: ProQR announces financial results for the second quarter of 2018 31
May 09, 2018: ProQR Announces Results for the First Quarter of 2018 32
Feb 28, 2018: ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update 34
Nov 20, 2017: ProQR Announces Results for the Third Quarter of 2017 37
Aug 16, 2017: ProQR Announces Results for the Second Quarter of 2017 39
May 17, 2017: ProQR Announces Results for the First Quarter of 2017 41
Feb 28, 2017: ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update 43
Corporate Communications 46
May 23, 2018: ProQR Appoints Yi-Tao Yu to Its Scientific Advisory Board 46
Nov 09, 2017: ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board 47
Oct 26, 2017: ProQR Announces Management Change and Key Promotions 48
Aug 28, 2017: ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong 49
Mar 27, 2017: ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer 50
Product News 51
Jun 15, 2017: ProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer, a novel proprietary RNA Technology 51
05/01/2017: ProQR to Present Data on QRX-411 at ARVO 53
05/01/2017: ProQR to Present Data on QRX-421 at ARVO 54
Product Approvals 55
Sep 05, 2017: ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA 55
Jul 05, 2017: ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA 56
Clinical Trials 57
Oct 24, 2017: ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference 57
Sep 25, 2017: ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis 58
Aug 29, 2017: ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial 60
Jun 08, 2017: ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ProQR Therapeutics NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ProQR Therapeutics NV, Deals By Therapy Area, 2012 to YTD 2018 9
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ProQR Therapeutics Enters into Agreement with EB Research Partnership and EB Medical Research Foundation 11
Foundation Fighting Blindness and ProQR Therapeutics Enter into Agreement 12
ProQR Therapeutics and Galapagos Enter into Research Agreeement 13
ProQR Therapeutics Signs License Agreement with Inserm Transfert and Assistance-Publique-Hopiteaux de Paris 14
ProQR Therapeutics Enters into Licensing Agreement with Leiden University Medical Center 15
ProQR Therapeutics Enters into Licensing Agreement with Cystic Fibrosis Foundation 16
ProQR Therapeutics Enters into Licensing Agreement with Radboud University Medical Center 17
ProQR Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 18
ProQR Therapeutics Raises USD104.1 Million in Public Offering of Shares 19
Proqr Therapeutics Prices Public Offering of Shares for USD16.1 Million 21
Proqr Therapeutics Prices Private Placement of Shares for USD4.6 Million 22
Amylon Therapeutics Spin Out from ProQR Therapeutics 23
ProQR Therapeutics to Raise USD6 Million in Private Placement of Shares 24
ProQR Therapeutics Raises USD112 Million in IPO 25
ProQR Therapeutics NV, Key Competitors 27
ProQR Therapeutics NV, Key Employees 28
ProQR Therapeutics NV, Other Locations 29
ProQR Therapeutics NV, Subsidiaries 29
List of Figures
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9